Lead Program, BPT567, will be the first PD1-IL18 immunoconjugate to enter the clinic; Phase 1/2a study in solid tumors expected to begin in 2H 2024

Lead计划BPT567将是第一个进入临床的PD1-IL18免疫偶联物；实体瘤1/2a期研究预计于2024年下半年开始

Financing led by Johnson & Johnson with participation by new and existing investors

由强生公司牵头，新投资者和现有投资者参与的融资

BASEL, Switzerland and SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation, multifunctional immunotherapies, today announced that it raised $90 million in a Series C financing. The round was led by Johnson & Johnson Innovation – JJDC, with participation from additional new investors Venrock, KB Investment, and Northleaf Capital Partners.

瑞士巴塞尔和圣地亚哥，2024年6月11日（环球通讯社）--开发下一代多功能免疫疗法的生物技术公司Bright Peak Therapeutics今天宣布，它在C系列融资中筹集了9000万美元。这一轮由强生创新（JJDC）牵头，其他新投资者Venrock、KB Investment和Northleaf Capital Partners也参与了。

Existing investors participating in the round include founding investor Versant Ventures along with Fidelity Management & Research Company, RA Capital Management, Qatar Investment Authority, Invus, Alexandria Venture Investments, and an undisclosed leading healthcare investment fund..

参与本轮投资的现有投资者包括创始投资者Versant Ventures，以及Fidelity Management&Research Company、RA Capital Management、卡塔尔投资管理局、Invus、Alexandria Venture Investments和一家未披露的领先医疗保健投资基金。

Proceeds from the Series C financing will be used to advance BPT567 into a Phase 1/2a clinical trial and accelerate a pipeline of next-generation immunotherapies. BPT567 is a first-in-class PD1-IL18 immunoconjugate designed to provide simultaneous blockade of the PD(L)-1 checkpoint pathway and targeted delivery of IL-18 signaling..

C系列融资的收益将用于将BPT567推进1/2a期临床试验，并加速下一代免疫疗法的开发。BPT567是一流的PD1-IL18免疫偶联物，旨在同时阻断PD（L）-1检查点途径和靶向传递IL-18信号。

In preclinical models, BPT567 induced profound synergistic anti-tumor activity by blocking PD-1 and specifically targeting the potent proinflammatory effects of IL-18 to effector T cells in the tumor microenvironment (TME) with more limited activation of immune cells in the periphery.

在临床前模型中，BPT567通过阻断PD-1并特异性靶向IL-18对肿瘤微环境（TME）中效应T细胞的有效促炎作用而诱导了显着的协同抗肿瘤活性，而外周免疫细胞的激活更为有限。

“We are now well positioned to bring much needed innovation to the field of anti-PD-1 immune-checkpoint inhibition and look forward to advancing our lead program into the clinic later this year across multiple tumor types” said Fredrik Wiklund, Chief Executive Officer of Bright Peak.

Bright Peak首席执行官弗雷德里克·维克隆德（FredrikWiklund）表示：“我们现在处于有利地位，可以为抗PD-1免疫检查点抑制领域带来急需的创新，并期待着今年晚些时候将我们的领先项目推进多种肿瘤类型的临床。”

“This capital raise provides financial flexibility to bring new therapeutic modalities to patients with cancer and we’re delighted to have attracted the confidence of a global pharmaceutical company and strong support from such a distinguished syndicate of leading life sciences investors.”

“此次融资提供了财务灵活性，为癌症患者带来了新的治疗方式，我们很高兴吸引了一家全球制药公司的信心，并得到了如此杰出的领先生命科学投资者财团的大力支持。”

About Bright Peak Therapeutics

关于Bright Peak Therapeutics

Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies to treat cancer and other diseases. We leverage our world class protein engineering capabilities and our proprietary chemical protein synthesis and conjugation platform to discover and develop first-in-class novel protein therapeutics.

Bright Peak Therapeutics是一家生物技术公司，致力于开发多功能免疫疗法组合，以治疗癌症和其他疾病。我们利用世界一流的蛋白质工程能力和专有的化学蛋白质合成和缀合平台来发现和开发一流的新型蛋白质疗法。

Bright Peak is based in Basel, Switzerland and San Diego, CA and is funded by a syndicate of leading healthcare investors. For more information, please visit www.brightpeaktx.com.

Bright Peak总部位于瑞士巴塞尔和加利福尼亚州圣地亚哥，由领先的医疗保健投资者组成的财团资助。有关更多信息，请访问www.brightpeaktx.com。